Clinical significance of sarcopenia in children with neuroblastic tumors
Topic overview
This study demonstrates that skeletal muscle index at diagnosis predicts survival in children with neuroblastic tumors and decreases significantly during treatment. Sarcopenia monitoring is crucial as muscle loss correlates with growth impairment in pediatric neuroblastoma patients.
Key takeaways
- Skeletal muscle index z-score (SMI-z) at diagnosis independently predicts overall survival in pediatric neuroblastic tumors (HR 0.58).
- SMI-z, height z-score, and weight z-score all significantly decline during treatment, while BMI-z remains stable.
- Sarcopenia may contribute to growth impairment in pediatric NT survivors, warranting routine muscle mass monitoring.
- BMI alone is insufficient to detect muscle loss in children with neuroblastic tumors undergoing treatment.
- Even disease-free high-risk NT survivors show progressive decline in muscle mass during follow-up.
Keywords
Hashtags
Full article text
Full article text not available for this entry
How to cite: GlobalCastMD. Clinical significance of sarcopenia in children with neuroblastic tumors. GlobalCastMD Medical Library. 2024-08-21. https://dev.library.globalcastmd.com/article/9048?via_space=staycurrentmd
Comments